These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28264642)

  • 1. Editorial: Targets for Immunotherapy in Acute Leukemia.
    Hourigan CS
    Curr Drug Targets; 2017; 18(3):256. PubMed ID: 28264642
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia.
    Tallman M
    J Natl Compr Canc Netw; 2018 May; 16(5S):656-659. PubMed ID: 29784749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune therapy of AML.
    Molldrem J
    Cytotherapy; 2002; 4(5):437-8. PubMed ID: 12473216
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel drug targets in acute leukemia.
    Stock W
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.
    Goswami M; Hourigan CS
    Curr Drug Targets; 2017; 18(3):296-303. PubMed ID: 25706110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current strategies in immunotherapy for acute myeloid leukemia.
    Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
    Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.
    Anguille S; Van Tendeloo VF; Berneman ZN
    Leukemia; 2012 Oct; 26(10):2186-96. PubMed ID: 22652755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Immunotherapy for acute myeloid leukaemia.
    Lancet; 1974 May; 1(7862):846-7. PubMed ID: 4132795
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in acute myeloid leukemia.
    Newell LF; Cook RJ
    BMJ; 2021 Oct; 375():n2026. PubMed ID: 34615640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.
    Gesundheit B; Shapira MY; Resnick IB; Amar A; Kristt D; Dray L; Budowski E; Or R
    Am J Hematol; 2009 Mar; 84(3):188-90. PubMed ID: 19105234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
    Saito Y; Nakahata S; Yamakawa N; Kaneda K; Ichihara E; Suekane A; Morishita K
    Leukemia; 2011 Jun; 25(6):921-31. PubMed ID: 21394097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in acute myeloid leukemia.
    Arpinati M; Curti A
    Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccines for patients with acute myeloid leukemia.
    Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
    Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
    Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of human acute leukemia: antibody response to leukemia-associated antigens.
    Baker MA; Falk JA; Taub RN
    Blood; 1978 Sep; 52(3):469-80. PubMed ID: 277268
    [No Abstract]   [Full Text] [Related]  

  • 19. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.
    Hofmann S; Götz M; Schneider V; Guillaume P; Bunjes D; Döhner H; Wiesneth M; Greiner J
    J Clin Oncol; 2013 Jan; 31(3):e44-7. PubMed ID: 23248243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.